Report Overview

The UK CNS Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The UKs market for CNS Therapeutics is driven by the urgent need to address the unmet medical needs of neurological disorders. The central nervous system drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. With unmet needs continuing to persist, societal and healthcare burden continues to increase.



Market Drivers

Advancements in diagnostics and therapeutics of central nervous system (CNS) diseases are expected to increase the treatment rate in UK. Moreover, the increasing prevalence of central nervous system disorders and the rising demand for effective therapeutics options are expected to boost market growth over the forecast years. Strong opportunities for CNS focussed drugs exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson's, Alzheimer's, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders.

The scenario has created a healthy pipeline of late-stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs. Increased demand for combination therapies, growing use of generics, and launch of new Alzheimer's drugs including anti amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines, and GABA receptor modulators, better understanding of the electrochemical processes of the brain and development of disease-modifying therapies is driving growth in the antiepileptic drugs market. Volume of CNS prescriptions for chronic pain and psychiatric disorders will grow in the coming years as the burden of mental illnesses intensifies because of lifestyle and societal changes and physiological stress. The growing focus on healthcare cost containment and rationalization and legislation of policies that encourage physician prescription of generic drugs will encourage sales of generic CNS medications.